Health & Environmental Research Online (HERO)


Print Feedback Export to File
7048467 
Journal Article 
Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study 
D'Urzo, AD; Rennard, SI; Kerwin, EM; Mergel, V; Leselbaum, AR; Caracta, CF; , 
2014 
1 
Respiratory Research
ISSN: 1465-9921
EISSN: 1465-993X 
BIOMED CENTRAL LTD 
LONDON 
25756831 
WOS:000346529400001 
Background: Combining two long-acting bronchodilators with complementary mechanisms of action may provide treatment benefits to patients with chronic obstructive pulmonary disease (COPD) that are greater than those derived from either treatment alone. The efficacy and safety of a fixed-dose combination (FDC) of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol fumarate, a long-acting beta(2)-agonist, in patients with moderate to severe COPD are presented.Methods: In this 24-week double-blind study, 1692 patients with stable COPD were equally randomized to twice-daily treatment with FDC aclidinium 400 mu g/formoterol 12 mu g (ACL400/FOR12 FDC), FDC aclidinium 400 mu g/formoterol 6 mu g (ACL400/FOR6 FDC), aclidinium 400 mu g, formoterol 12 mu g, or placebo administered by a multidose dry powder inhaler (Genuair(R)/Pressair(R))*. Coprimary endpoints were change from baseline to week 24 in 1-hour morning postdose FEV1 (FDCs versus aclidinium) and change from baseline to week 24 in morning predose (trough) FEV1 (FDCs versus formoterol). Secondary endpoints were change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score and improvement in Transition Dyspnea Index (TDI) focal score at week 24. Safety and tolerability were also assessed.Results: At study end, improvements from baseline in 1-hour postdose FEV1 were significantly greater in patients treated with ACL400/FOR12 FDC or ACL400/FOR6 FDC compared with aclidinium (108 mL and 87 mL, respectively; p < 0.0001). Improvements in trough FEV1 were significantly greater in patients treated with ACL400/FOR12 FDC versus formoterol (45 mL; p = 0.0102), a numerical improvement of 26 mL in trough FEV1 over formoterol was observed with ACL400/FOR6 FDC. Significant improvements in both SGRQ total and TDI focal scores were observed in the ACL400/FOR12 FDC group at study end (p < 0.0001), with differences over placebo exceeding the minimal clinically important difference of >= 4 points and >= 1 unit, respectively. All treatments were well tolerated, with safety profiles of the FDCs similar to those of the monotherapies.Conclusions: Treatment with twice-daily aclidinium 400 mu g/formoterol 12 mu g FDC provided rapid and sustained bronchodilation that was greater than either monotherapy; clinically significant improvements in dyspnea and health status were evident compared with placebo. Aclidinium/formoterol FDC may be an effective and well tolerated new treatment option for patients with COPD.